Moreover, in this study, MS patients had significantly lower plasma leptin levels than controls, suggesting that future studies should account for all factors influencing leptin levels to clarify its controversial outcomes in MS pathogenesis and progression [229]. This evidence concerns the gene LEP and myeloid sarcoma.